Scribd Logo
Upload

Welcome to Scribd!

    • 272 views

    Memo

    Uploaded by

    Smart Heart
    - Arvophillia infects 27% of the population, with 0.5 million severe cases that have a 100% mortality rate without treatment. Huffstatin has been the main treatment since the 1960s but has several drawbacks. - Clairadol is a safer, easier to administer alternative to Huffstatin that has shown in clinical trials to reduce mortality rates for both adults and children with severe Arvophillia. - Based on WHO endorsement and evidence from clinical trials demonstrating benefits in mortality as well as fewer side effects, CHAI recommends that the Ministry of Health of Zachistan switch to Clairadol as the preferred treatment for severe Arvophillia cases

    Copyright:

    © All Rights Reserved
    Download as DOC, PDF, TXT or read online from Scribd

    Memo

    Uploaded by

    Smart Heart
    272 views1 page
    - Arvophillia infects 27% of the population, with 0.5 million severe cases that have a 100% mortality rate without treatment. Huffstatin has been the main treatment since the 1960s but has several drawbacks. - Clairadol is a safer, easier to administer alternative to Huffstatin that has shown in clinical trials to reduce mortality rates for both adults and children with severe Arvophillia. - Based on WHO endorsement and evidence from clinical trials demonstrating benefits in mortality as well as fewer side effects, CHAI recommends that the Ministry of Health of Zachistan switch to Clairadol as the preferred treatment for severe Arvophillia cases

    Original Title

    Memo.doc

    Copyright

    © © All Rights Reserved

    Available Formats

    DOC, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    - Arvophillia infects 27% of the population, with 0.5 million severe cases that have a 100% mortality rate without treatment. Huffstatin has been the main treatment since the 1960s but has several drawbacks. - Clairadol is a safer, easier to administer alternative to Huffstatin that has shown in clinical trials to reduce mortality rates for both adults and children with severe Arvophillia. - Based on WHO endorsement and evidence from clinical trials demonstrating benefits in mortality as well as fewer side effects, CHAI recommends that the Ministry of Health of Zachistan switch to Clairadol as the preferred treatment for severe Arvophillia cases

    Copyright:

    © All Rights Reserved
    Download as DOC, PDF, TXT or read online from Scribd
    Download as doc, pdf, or txt
    272 views1 page

    Memo

    Uploaded by

    Smart Heart
    - Arvophillia infects 27% of the population, with 0.5 million severe cases that have a 100% mortality rate without treatment. Huffstatin has been the main treatment since the 1960s but has several drawbacks. - Clairadol is a safer, easier to administer alternative to Huffstatin that has shown in clinical trials to reduce mortality rates for both adults and children with severe Arvophillia. - Based on WHO endorsement and evidence from clinical trials demonstrating benefits in mortality as well as fewer side effects, CHAI recommends that the Ministry of Health of Zachistan switch to Clairadol as the preferred treatment for severe Arvophillia cases

    Copyright:

    © All Rights Reserved
    Download as DOC, PDF, TXT or read online from Scribd
    Download as doc, pdf, or txt
    You are on page 1of 1

    Memo

    Arvophillia is an infectious that has been diagnosed in 27% of total population 34.6 million. Nearly 0.5
    million of people (5% of all diagnosed cases) are severe cases. Without treatment, these severe cases
    have 100% mortality rate.

    Huffstatin has been the mainstay treatment for arvophillia since 1960s. In the treatment of severe
    arvophillia, huffstatin is given three times a day in a slow, rate-controlled intravenous (IV) drip over four
    hours per IV drip. The drawbacks of huffstatin treatment protocol includes: increase burden on health
    care workers as it requires continual supervision and monitoring for huffstatin associated side effects
    and may lead to extremely low blood sugar that can cause brain damage and developmental delays in
    children.

    Clairadol is a highly effective alternative option to huffstatin. It is safer and easier to administer than
    huffstatin. Therefore, lowering side effects usually associated the administration of huffstatin. Clairadol
    with quality standards is now available from verified and pre-approved suppliers.

    There are two clinical trials: NEEDAN conducted in 2005 which was primarily conducted on adults in
    South East Asia and MENDLAK conducted in 2010 which was conducted on children living in nine
    different African countries. Those trials demonstrated that clairadol can reduce mortality rate 7% in
    adults (over 14 years old) and 2.4% in children (under 14 years old).

    In addition to mortality benefit, clairadol have clinical benefits such as lower risk of hypoglycemia, less
    frequent development of coma and less frequent convulsions and programmatic benefits such as less
    burden on health care workers, fewer doses to complete treatment, safer drug administration. World
    Health Organization (WHO) updated its guideline for the treatment of severe arvophillia and now
    recommends: “Clairadol as the preferred treatment for both adults and children in the treatment of
    Severe Arvophillia”.

    In terms of cost per person, clairadol will cost additional 2.74 USD over huffstatin in under 3 years old
    severe cases and average additional cost of 5.21 USD over all ages of severe cases. By spending those
    additional cost over diagnosed severe cases, it can save additional 14,000 lives over huffstatin. Although
    cost per life saved over huffstatin is 155.69 USD, it can be reduced further by using optimal unit size of
    one vial according to demographic distribution of severe patients.

    As based upon WHO’s endorsement of clairadol as the most effective treatment for server arvophillia,
    proven clinical trials with benefits in mortality rate, clinical and programmatic procedures and future
    possibility of reducing treatment cost, CHAI strongly recommends the Ministry of Health of Zachistan to
    switch clairadol as the preferred treatment for severe arvophillia cases.

    You might also like